Skip to main content
OpenTrials
Completed

NCT Number: NCT04281511

A Longitudinal, Observational Biomarker Study in Pancreatic Cancer Patients Receiving Chemotherapy

1. Based on the literature, the pancreatic cancer treatment predictor biomarker, which is used in the domestic clinical field, is actually applied to the pancreatic cancer patient cohort of the National Cancer Center. 2. To systematically prospectively identify prospective treatment response biomarkers for Pancreatic Cancer Cohort in the National Cancer Center

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Pancreatic Cancer Digestive System Diseases Digestive System Neoplasms Endocrine Gland Neoplasms Endocrine System Diseases Neoplasms Neoplasms by Site Pancreatic Diseases Pancreatic Neoplasms

Sex eligibility

All sexes

Study type

Observational

Primary location

NATIONAL CANCER CENTER 323, Ilsan-ro, Ilsandong-gu,

Goyang-si, Gyeonggi-do, 10408, South Korea

About this study

  • Immunohistochemistry and gene test for hENT1, DCK, SMAD4, CES2, BRCA 1/2,PALB2, MMRd, MSI, Tumor Ag and etc. on Cancer sample
  • Collect data of Biomarker for pancreatic cancer
  • Compare with Big data and Cohort study in National cancer center
  • The number of subjects is changed by statistical consideration. 218->238

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Pathologically Confirmed Pancreatic Cancer Patients

Exclusion criteria

  • Subjects who do not agree with the study

Treatment and study plan

Primary outcomes

  1. median survival

    Time frame: 5 years

    The length of time from either the date of diagnosis or the start of treatment for a disease,the length of time during and after the treatment of a disease, such as cancer, that a patient lives with the disease but it does not get worse

  2. progressive-free survival

    Time frame: 5 years

    The length of time during and after the treatment of a disease, such as cancer, that a patient lives with the disease but it does not get worse

Sponsors and collaborators

Lead sponsor

National Cancer Center, Korea

Other Gov

Registry information

Important dates

Study start
2019
Primary completion
2023
Study completion
2023
First posted
Feb 24, 2020
Registry last updated
Nov 13, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.